ESOPREDICT® Barrett's Esophagus Risk Classifier Assay
Esophageal cancer ranks sixth among cancer-related deaths worldwide, with two primary subtypes: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), the latter being strongly linked to Barrett’s Esophagus (BE). BE is a condition where chronic exposure to gastric acid reflux induces metaplastic transformation of normal esophageal squamous epithelium into columnar epithelium, significantly increasing the risk of progression to EAC. The estimated prevalence of BE in the U.S. is 5.6%.
The current standard for esophageal carcinoma risk stratification in BE patients relies on histological grading of dysplasia such as, Non-dysplastic Barrett's esophagus (ND-BE), Indefinite for dysplasia (IFD), Low-grade dysplasia (LGD) and High-grade dysplasia (HGD). However, histopathological assessment is subject to inter-observer variability, leading to inconsistent risk stratification. Not all patients with BE progress to cancer, yet late-stage diagnosis results in poor prognosis. Early identification of high-risk individuals (progressors) is critical to implementing timely surveillance and intervention.
ESOPREDICT is a molecular diagnostic assay utilizing DNA methylation analysis of four key tumor suppressor genes (HPP1, RUNX3, P16, FBN1) implicated in BE progression to cancer. This test provides an objective risk classification for BE patients based on a proprietary methylation-based risk score (0–10). This test is clinically valuable in guiding risk-based surveillance strategies, reducing unnecessary invasive endoscopic procedures for low-risk individuals, and ensuring active intervention for high-risk progressors.
- Identifies BE patients at high risk for progression to esophageal adenocarcinoma
- Assists in risk stratification and management of BE patients
- Reduces unnecessary endoscopic surveillance in low-risk individuals
- Guides intensive monitoring or early therapeutic intervention for high-risk patients
Risk Score Clinical Recommendation
- Low Risk (0-2.5) No surveillance required for up to 5 years
- Low-Moderate Risk (2.6-5.0) Endoscopic surveillance every 3 years
- High-Moderate Risk (5.1-7.5) Intensive surveillance or endoscopic eradication therapy
- High Risk (7.6-10.0) Immediate endoscopic eradication therapy recommended
Results are correlated with the 5-year probability of progression to high-grade dysplasia or esophageal adenocarcinoma.
Low Risk: 0-2.5
Low-Moderate Risk: 2.6-5.0
High-Moderate Risk: 5.1-7.5
High Risk: 7.6-10.0
Formalin-Fixed Paraffin-Embedded (FFPE) Tissue.
Stability
- Room temperature
- Gastrointest Endosc. 2017 May;85(5):889-903. [PMID: 28109913]
- Am J Gastroenterol. 2022 Apr 1;117(4):559-587. [PMID: 35354777]
- Clin Cancer Res. 2019 Apr 1;25(7):2127-2135. [PMID: 30670490]
- Aging (Albany NY). 2019 Dec 13;11(23):11640-11658. [PMID: 31834866]
- Cancer Res. 2009 May 15;69(10):4112-5. [PMID: 19435894]
- Clin Gastroenterol Hepatol. 2022 Dec;20(12):2772-2779.e8. [PMID: 35217151]